InvestorsHub Logo
Followers 63
Posts 8502
Boards Moderated 0
Alias Born 01/10/2014

Re: None

Friday, 11/29/2019 12:08:42 PM

Friday, November 29, 2019 12:08:42 PM

Post# of 425689
Make certain you are loaded up prior to Dec 28th. With 100% endorsement going into the meeting AMRN will pop huge.

Amarin's Vascepa Faces Final Hurdle After Unanimous FDA Panel Backing

Company: Amarin Corporation plc (NASDAQ: AMRN)
Type of Application: sNDA
Candidate: Vascepa
Indication: Reduce the risk of cardiovascular events
Date: Dec. 28
An FDA panel that met in mid-November unanimously recommended approval of Vascepa to reduce the risk of cardiovascular events in high-risk patients.


Statements made are only my opinion. Do your own DD in order to make your Investment decisions.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News